Robert Freedman
Concepts (531)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 72 | 2020 | 446 | 8.780 |
Why?
| | Choline | 12 | 2024 | 136 | 4.640 |
Why?
| | Evoked Potentials, Auditory | 39 | 2024 | 180 | 3.610 |
Why?
| | Receptors, Nicotinic | 37 | 2013 | 321 | 3.420 |
Why?
| | Nicotinic Agonists | 15 | 2016 | 136 | 3.250 |
Why?
| | Brain | 35 | 2021 | 2933 | 2.420 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 24 | 2016 | 93 | 2.290 |
Why?
| | Hippocampus | 31 | 2013 | 965 | 2.000 |
Why?
| | Psychotic Disorders | 9 | 2021 | 186 | 1.880 |
Why?
| | Hot Flashes | 7 | 2014 | 88 | 1.820 |
Why?
| | Prenatal Exposure Delayed Effects | 8 | 2021 | 675 | 1.800 |
Why?
| | Neural Inhibition | 17 | 2013 | 178 | 1.730 |
Why?
| | Sensory Gating | 8 | 2020 | 44 | 1.730 |
Why?
| | Psychiatry | 5 | 2018 | 193 | 1.720 |
Why?
| | Benzylidene Compounds | 8 | 2013 | 20 | 1.670 |
Why?
| | Schizophrenic Psychology | 19 | 2015 | 97 | 1.660 |
Why?
| | Periodicals as Topic | 5 | 2018 | 203 | 1.610 |
Why?
| | Folic Acid | 4 | 2024 | 199 | 1.490 |
Why?
| | Pregnancy Complications, Infectious | 4 | 2021 | 428 | 1.430 |
Why?
| | Fetal Development | 9 | 2024 | 299 | 1.410 |
Why?
| | Nicotine | 17 | 2013 | 331 | 1.410 |
Why?
| | Pyridines | 8 | 2013 | 605 | 1.210 |
Why?
| | Antidepressive Agents | 3 | 2023 | 248 | 1.190 |
Why?
| | Chromosomes, Human, Pair 15 | 16 | 2015 | 50 | 1.170 |
Why?
| | Attention | 18 | 2020 | 457 | 1.170 |
Why?
| | Ketamine | 2 | 2023 | 132 | 1.140 |
Why?
| | Gestational Age | 6 | 2024 | 975 | 1.100 |
Why?
| | Pursuit, Smooth | 9 | 2007 | 19 | 1.090 |
Why?
| | Maternal Exposure | 2 | 2019 | 213 | 1.010 |
Why?
| | Pregnancy | 18 | 2024 | 7190 | 0.930 |
Why?
| | Acoustic Stimulation | 20 | 2020 | 333 | 0.910 |
Why?
| | Menopause | 4 | 2014 | 320 | 0.900 |
Why?
| | Mental Disorders | 5 | 2021 | 1168 | 0.850 |
Why?
| | Evoked Potentials | 7 | 2020 | 128 | 0.830 |
Why?
| | Child Behavior | 2 | 2016 | 236 | 0.800 |
Why?
| | Child Development | 5 | 2024 | 484 | 0.790 |
Why?
| | Electroconvulsive Therapy | 1 | 2023 | 15 | 0.790 |
Why?
| | Dietary Supplements | 5 | 2021 | 576 | 0.780 |
Why?
| | Humans | 125 | 2024 | 144759 | 0.760 |
Why?
| | Auditory Perception | 8 | 2004 | 114 | 0.750 |
Why?
| | Prenatal Care | 4 | 2021 | 307 | 0.750 |
Why?
| | Body Temperature Regulation | 4 | 2013 | 108 | 0.730 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 109 | 0.710 |
Why?
| | Reflex, Startle | 3 | 2014 | 76 | 0.710 |
Why?
| | Phosphatidylcholines | 3 | 2018 | 131 | 0.700 |
Why?
| | Antipsychotic Agents | 8 | 2008 | 213 | 0.680 |
Why?
| | Micronutrients | 2 | 2021 | 96 | 0.680 |
Why?
| | Infant Behavior | 2 | 2020 | 26 | 0.670 |
Why?
| | Infant, Newborn | 10 | 2024 | 6429 | 0.650 |
Why?
| | Female | 74 | 2024 | 78271 | 0.650 |
Why?
| | Smoking | 14 | 2013 | 1472 | 0.640 |
Why?
| | Brain Mapping | 6 | 2013 | 536 | 0.630 |
Why?
| | Adult | 55 | 2024 | 40449 | 0.610 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 2 | 2018 | 56 | 0.600 |
Why?
| | Prefrontal Cortex | 3 | 2016 | 328 | 0.600 |
Why?
| | Neurons | 10 | 2019 | 1640 | 0.590 |
Why?
| | Hallucinogens | 1 | 2021 | 108 | 0.570 |
Why?
| | Editorial Policies | 2 | 2018 | 46 | 0.570 |
Why?
| | Magnetic Resonance Imaging | 13 | 2013 | 3863 | 0.570 |
Why?
| | Endophenotypes | 2 | 2015 | 21 | 0.570 |
Why?
| | Perceptual Disorders | 3 | 2005 | 25 | 0.570 |
Why?
| | Electroencephalography | 11 | 2020 | 532 | 0.560 |
Why?
| | Saccades | 7 | 2007 | 45 | 0.560 |
Why?
| | Male | 79 | 2024 | 72315 | 0.550 |
Why?
| | C-Reactive Protein | 4 | 2022 | 416 | 0.550 |
Why?
| | Hydrocortisone | 1 | 2020 | 304 | 0.550 |
Why?
| | Nootropic Agents | 2 | 2020 | 30 | 0.540 |
Why?
| | Premature Birth | 1 | 2021 | 380 | 0.510 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.510 |
Why?
| | Problem Behavior | 1 | 2018 | 102 | 0.500 |
Why?
| | Primary Prevention | 1 | 2018 | 220 | 0.470 |
Why?
| | Interneurons | 6 | 2001 | 128 | 0.470 |
Why?
| | Arousal | 6 | 1993 | 157 | 0.470 |
Why?
| | Image Processing, Computer-Assisted | 6 | 2013 | 780 | 0.470 |
Why?
| | Depression | 2 | 2023 | 1558 | 0.470 |
Why?
| | Marijuana Smoking | 1 | 2019 | 250 | 0.470 |
Why?
| | Psychological Trauma | 1 | 2016 | 57 | 0.470 |
Why?
| | Validation Studies as Topic | 1 | 2015 | 23 | 0.450 |
Why?
| | Afferent Pathways | 3 | 2013 | 46 | 0.450 |
Why?
| | Cognition Disorders | 3 | 2010 | 538 | 0.440 |
Why?
| | Bungarotoxins | 10 | 2008 | 45 | 0.430 |
Why?
| | Amygdala | 1 | 2016 | 198 | 0.430 |
Why?
| | Genotype | 9 | 2015 | 1833 | 0.430 |
Why?
| | Sleep | 4 | 2014 | 901 | 0.420 |
Why?
| | Aggression | 1 | 2016 | 179 | 0.420 |
Why?
| | Sleep, REM | 3 | 2006 | 44 | 0.420 |
Why?
| | Reaction Time | 7 | 2020 | 438 | 0.410 |
Why?
| | Teaching | 1 | 2016 | 236 | 0.400 |
Why?
| | Cannabis | 1 | 2021 | 509 | 0.400 |
Why?
| | Eye Movements | 4 | 2013 | 92 | 0.390 |
Why?
| | Phosphorylcholine | 1 | 2013 | 19 | 0.390 |
Why?
| | Gyrus Cinguli | 4 | 2006 | 96 | 0.380 |
Why?
| | Sleep Apnea Syndromes | 1 | 2014 | 97 | 0.380 |
Why?
| | Neural Pathways | 4 | 2010 | 311 | 0.380 |
Why?
| | Genetic Linkage | 10 | 2012 | 273 | 0.370 |
Why?
| | Mothers | 5 | 2021 | 775 | 0.370 |
Why?
| | Double-Blind Method | 6 | 2016 | 2029 | 0.360 |
Why?
| | Neuropsychological Tests | 6 | 2016 | 1134 | 0.360 |
Why?
| | Clozapine | 4 | 2004 | 20 | 0.350 |
Why?
| | Ocular Motility Disorders | 2 | 2004 | 41 | 0.350 |
Why?
| | Cerebral Cortex | 6 | 2006 | 464 | 0.340 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 412 | 0.340 |
Why?
| | Emotions | 2 | 2016 | 578 | 0.330 |
Why?
| | Nicotinic Antagonists | 6 | 2008 | 35 | 0.310 |
Why?
| | 5-Hydroxytryptophan | 1 | 2009 | 19 | 0.310 |
Why?
| | Middle Aged | 30 | 2016 | 35875 | 0.310 |
Why?
| | Dopamine | 7 | 2009 | 283 | 0.310 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 44 | 0.300 |
Why?
| | Cognition | 3 | 2016 | 1266 | 0.300 |
Why?
| | Schizotypal Personality Disorder | 2 | 2002 | 11 | 0.300 |
Why?
| | Sensation Disorders | 2 | 2007 | 41 | 0.300 |
Why?
| | Peer Review, Research | 1 | 2009 | 36 | 0.300 |
Why?
| | Fetus | 4 | 2021 | 803 | 0.290 |
Why?
| | Cocaine-Related Disorders | 2 | 2001 | 132 | 0.290 |
Why?
| | Infant | 9 | 2021 | 10034 | 0.290 |
Why?
| | Biomedical Research | 1 | 2015 | 710 | 0.290 |
Why?
| | Thalamus | 2 | 2007 | 125 | 0.290 |
Why?
| | Mice, Inbred DBA | 4 | 2008 | 187 | 0.280 |
Why?
| | Nitric Oxide Synthase | 2 | 2000 | 235 | 0.280 |
Why?
| | Writing | 1 | 2009 | 100 | 0.280 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2007 | 186 | 0.280 |
Why?
| | Body Temperature | 2 | 2007 | 229 | 0.270 |
Why?
| | Sensory Aids | 1 | 2007 | 4 | 0.260 |
Why?
| | Child, Preschool | 6 | 2024 | 11787 | 0.260 |
Why?
| | Miniaturization | 1 | 2007 | 22 | 0.260 |
Why?
| | Neurons, Afferent | 2 | 1999 | 102 | 0.260 |
Why?
| | Auditory Perceptual Disorders | 3 | 2008 | 8 | 0.260 |
Why?
| | Equipment and Supplies | 1 | 2007 | 35 | 0.260 |
Why?
| | Neostriatum | 1 | 2007 | 37 | 0.260 |
Why?
| | Synaptic Transmission | 6 | 2024 | 290 | 0.250 |
Why?
| | Humidity | 1 | 2007 | 52 | 0.250 |
Why?
| | Learning | 2 | 2009 | 452 | 0.250 |
Why?
| | Contingent Negative Variation | 2 | 2005 | 9 | 0.250 |
Why?
| | Phenotype | 7 | 2018 | 3162 | 0.250 |
Why?
| | Genetic Markers | 7 | 2012 | 331 | 0.240 |
Why?
| | Child of Impaired Parents | 2 | 1996 | 38 | 0.240 |
Why?
| | Pedigree | 8 | 2009 | 514 | 0.240 |
Why?
| | Acetylcholine | 3 | 2002 | 204 | 0.240 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2005 | 14 | 0.240 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2005 | 11 | 0.240 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.230 |
Why?
| | Biomarkers | 3 | 2015 | 4271 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2363 | 0.230 |
Why?
| | Animals | 34 | 2021 | 38058 | 0.230 |
Why?
| | Internship and Residency | 1 | 2016 | 1257 | 0.220 |
Why?
| | Sensation | 3 | 1991 | 55 | 0.220 |
Why?
| | Galvanic Skin Response | 3 | 2013 | 26 | 0.220 |
Why?
| | Receptors, Cholinergic | 5 | 2009 | 41 | 0.220 |
Why?
| | Child | 9 | 2021 | 22633 | 0.220 |
Why?
| | Reference Values | 8 | 2002 | 797 | 0.220 |
Why?
| | Time Perception | 1 | 2005 | 33 | 0.210 |
Why?
| | Mice, Inbred C3H | 2 | 2001 | 251 | 0.210 |
Why?
| | Cross-Over Studies | 3 | 2016 | 601 | 0.200 |
Why?
| | Sleep Deprivation | 1 | 2006 | 206 | 0.200 |
Why?
| | Norepinephrine | 5 | 1992 | 196 | 0.200 |
Why?
| | Young Adult | 5 | 2022 | 14105 | 0.190 |
Why?
| | Bipolar Disorder | 4 | 2007 | 280 | 0.190 |
Why?
| | Pyramidal Cells | 3 | 2003 | 79 | 0.190 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 23 | 0.190 |
Why?
| | Homovanillic Acid | 5 | 1990 | 8 | 0.190 |
Why?
| | Promoter Regions, Genetic | 4 | 2003 | 1257 | 0.190 |
Why?
| | Publishing | 2 | 2016 | 114 | 0.180 |
Why?
| | Wakefulness | 2 | 2001 | 169 | 0.180 |
Why?
| | Linkage Disequilibrium | 2 | 2009 | 246 | 0.180 |
Why?
| | Hearing Disorders | 1 | 2001 | 10 | 0.170 |
Why?
| | Rats | 16 | 2002 | 5597 | 0.170 |
Why?
| | Social Problems | 1 | 2021 | 10 | 0.170 |
Why?
| | Vitamin A | 1 | 2021 | 59 | 0.170 |
Why?
| | Phencyclidine | 3 | 1992 | 4 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2010 | 2027 | 0.160 |
Why?
| | Reward | 1 | 2023 | 247 | 0.160 |
Why?
| | Vitamin D | 2 | 2021 | 400 | 0.160 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2021 | 142 | 0.160 |
Why?
| | Frontal Lobe | 3 | 2006 | 160 | 0.160 |
Why?
| | Oxygen | 3 | 2013 | 995 | 0.160 |
Why?
| | Sweating | 2 | 2013 | 41 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 2608 | 0.160 |
Why?
| | Vitamins | 1 | 2021 | 178 | 0.150 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2004 | 428 | 0.150 |
Why?
| | Object Attachment | 1 | 2020 | 48 | 0.150 |
Why?
| | Chromosome Mapping | 4 | 2009 | 510 | 0.150 |
Why?
| | Schizophrenia, Childhood | 1 | 1999 | 3 | 0.150 |
Why?
| | Analysis of Variance | 5 | 2008 | 1306 | 0.150 |
Why?
| | Bombesin | 1 | 1999 | 10 | 0.150 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2005 | 541 | 0.150 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 165 | 0.150 |
Why?
| | Genetic Variation | 3 | 2003 | 983 | 0.150 |
Why?
| | Alleles | 5 | 2009 | 879 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 8 | 2002 | 2527 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 198 | 0.140 |
Why?
| | Maternal Age | 1 | 2019 | 126 | 0.140 |
Why?
| | Logistic Models | 2 | 2022 | 2117 | 0.140 |
Why?
| | Disease Models, Animal | 8 | 2009 | 4557 | 0.140 |
Why?
| | Catecholamines | 3 | 2002 | 87 | 0.140 |
Why?
| | Nutritional Status | 1 | 2021 | 354 | 0.140 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2013 | 46 | 0.140 |
Why?
| | DNA Mutational Analysis | 3 | 2013 | 406 | 0.140 |
Why?
| | Stem Cells | 1 | 2002 | 626 | 0.140 |
Why?
| | Risk Factors | 10 | 2021 | 10779 | 0.140 |
Why?
| | Psychomotor Performance | 4 | 2005 | 328 | 0.140 |
Why?
| | RNA, Messenger | 7 | 2006 | 2832 | 0.140 |
Why?
| | History, 21st Century | 1 | 2018 | 219 | 0.130 |
Why?
| | Irritable Mood | 1 | 2018 | 50 | 0.130 |
Why?
| | Dentate Gyrus | 1 | 1997 | 40 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2012 | 2145 | 0.130 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 905 | 0.130 |
Why?
| | Postmortem Changes | 3 | 2006 | 17 | 0.130 |
Why?
| | Adolescent | 12 | 2017 | 22428 | 0.130 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2017 | 31 | 0.130 |
Why?
| | Family | 4 | 2015 | 679 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 202 | 0.120 |
Why?
| | Neurocognitive Disorders | 1 | 1996 | 33 | 0.120 |
Why?
| | Gene Expression | 5 | 2006 | 1490 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 1998 | 372 | 0.120 |
Why?
| | Electrophysiology | 6 | 2003 | 218 | 0.120 |
Why?
| | Chewing Gum | 2 | 2007 | 8 | 0.120 |
Why?
| | Skin Temperature | 2 | 2006 | 36 | 0.120 |
Why?
| | Prepulse Inhibition | 1 | 2015 | 12 | 0.120 |
Why?
| | Nitric Oxide | 1 | 2000 | 897 | 0.110 |
Why?
| | Vanilmandelic Acid | 4 | 1990 | 4 | 0.110 |
Why?
| | Methoxyhydroxyphenylglycol | 4 | 1990 | 13 | 0.110 |
Why?
| | Benzodiazepines | 2 | 2008 | 167 | 0.110 |
Why?
| | Treatment Outcome | 2 | 2023 | 11679 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Twins | 1 | 1996 | 156 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1694 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2002 | 2050 | 0.110 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2013 | 151 | 0.110 |
Why?
| | Cerebrovascular Circulation | 2 | 2007 | 280 | 0.110 |
Why?
| | Electromyography | 3 | 2005 | 415 | 0.110 |
Why?
| | Postmenopause | 2 | 2007 | 391 | 0.110 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 397 | 0.110 |
Why?
| | Snoring | 1 | 2014 | 18 | 0.110 |
Why?
| | Synapsins | 1 | 1993 | 13 | 0.100 |
Why?
| | Synaptophysin | 1 | 1993 | 15 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 33 | 0.100 |
Why?
| | Hot Temperature | 2 | 2007 | 407 | 0.100 |
Why?
| | Corpus Striatum | 2 | 1992 | 179 | 0.100 |
Why?
| | Cerebellum | 5 | 2002 | 223 | 0.100 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2003 | 26 | 0.100 |
Why?
| | Polymorphism, Genetic | 4 | 2009 | 612 | 0.100 |
Why?
| | Sleep Stages | 1 | 1993 | 75 | 0.100 |
Why?
| | Brain Tissue Transplantation | 1 | 1992 | 19 | 0.100 |
Why?
| | Fetal Tissue Transplantation | 1 | 1992 | 33 | 0.100 |
Why?
| | Mesencephalon | 1 | 1992 | 64 | 0.090 |
Why?
| | Zinc | 1 | 1995 | 295 | 0.090 |
Why?
| | Parasympathetic Nervous System | 1 | 1992 | 26 | 0.090 |
Why?
| | Auditory Pathways | 1 | 1992 | 53 | 0.090 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 144 | 0.090 |
Why?
| | Genomics | 1 | 2018 | 834 | 0.090 |
Why?
| | Perinatal Care | 1 | 2013 | 62 | 0.090 |
Why?
| | Functional Laterality | 1 | 2013 | 241 | 0.090 |
Why?
| | Heart Rate | 2 | 2007 | 855 | 0.090 |
Why?
| | Immunity | 1 | 2013 | 139 | 0.090 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2003 | 192 | 0.090 |
Why?
| | Iodine Radioisotopes | 4 | 2001 | 136 | 0.090 |
Why?
| | Gene Frequency | 2 | 2005 | 481 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2015 | 2925 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1152 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2878 | 0.090 |
Why?
| | Alcoholism | 3 | 2003 | 817 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 2019 | 592 | 0.090 |
Why?
| | United States | 3 | 2018 | 15966 | 0.090 |
Why?
| | Gene Duplication | 3 | 2015 | 67 | 0.090 |
Why?
| | Blood Pressure | 3 | 2007 | 1769 | 0.090 |
Why?
| | Memory | 1 | 2013 | 295 | 0.080 |
Why?
| | Administration, Oral | 2 | 2005 | 847 | 0.080 |
Why?
| | Circadian Rhythm | 2 | 2013 | 514 | 0.080 |
Why?
| | Event-Related Potentials, P300 | 2 | 2003 | 15 | 0.080 |
Why?
| | Time Factors | 4 | 2005 | 7173 | 0.080 |
Why?
| | Aged | 10 | 2015 | 25913 | 0.080 |
Why?
| | Photic Stimulation | 2 | 2002 | 264 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 372 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2012 | 3604 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2014 | 300 | 0.080 |
Why?
| | Mice | 8 | 2009 | 18339 | 0.080 |
Why?
| | Electrooculography | 2 | 2001 | 12 | 0.070 |
Why?
| | Alprazolam | 1 | 1988 | 6 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2009 | 193 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 373 | 0.070 |
Why?
| | Education, Distance | 1 | 2009 | 61 | 0.070 |
Why?
| | Lorazepam | 1 | 1988 | 25 | 0.070 |
Why?
| | Diazepam | 1 | 1988 | 33 | 0.070 |
Why?
| | Field Dependence-Independence | 1 | 2008 | 6 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 96 | 0.070 |
Why?
| | Rats, Inbred Strains | 6 | 1992 | 321 | 0.070 |
Why?
| | Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.070 |
Why?
| | Glycols | 1 | 1988 | 5 | 0.070 |
Why?
| | Risk | 2 | 2002 | 911 | 0.070 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 1988 | 39 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5408 | 0.070 |
Why?
| | Dihydro-beta-Erythroidine | 2 | 2008 | 6 | 0.070 |
Why?
| | Genes | 2 | 1998 | 226 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5868 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1289 | 0.060 |
Why?
| | Nerve Net | 2 | 2002 | 285 | 0.060 |
Why?
| | Diseases in Twins | 1 | 1988 | 115 | 0.060 |
Why?
| | Models, Neurological | 2 | 2000 | 254 | 0.060 |
Why?
| | Auditory Cortex | 1 | 2007 | 47 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2012 | 157 | 0.060 |
Why?
| | Prospective Studies | 1 | 2019 | 7990 | 0.060 |
Why?
| | Depressive Disorder | 1 | 1990 | 387 | 0.060 |
Why?
| | Monitoring, Ambulatory | 1 | 2007 | 88 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1720 | 0.060 |
Why?
| | Parkinson Disease | 1 | 1992 | 600 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 779 | 0.060 |
Why?
| | Drug Interactions | 2 | 2008 | 398 | 0.060 |
Why?
| | Telemetry | 1 | 2005 | 41 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 1985 | 0.060 |
Why?
| | Genome | 2 | 2006 | 306 | 0.060 |
Why?
| | Memory, Short-Term | 1 | 2008 | 271 | 0.060 |
Why?
| | Menstrual Cycle | 1 | 2006 | 140 | 0.050 |
Why?
| | Sequence Analysis, DNA | 3 | 2003 | 824 | 0.050 |
Why?
| | Quetiapine Fumarate | 1 | 2004 | 26 | 0.050 |
Why?
| | Dibenzothiazepines | 1 | 2004 | 18 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2005 | 284 | 0.050 |
Why?
| | Risperidone | 1 | 2004 | 29 | 0.050 |
Why?
| | Parietal Lobe | 1 | 2005 | 60 | 0.050 |
Why?
| | Cold Temperature | 1 | 2006 | 209 | 0.050 |
Why?
| | Visual Pathways | 1 | 2005 | 61 | 0.050 |
Why?
| | Internet | 1 | 2009 | 699 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 2115 | 0.050 |
Why?
| | Verbal Behavior | 1 | 2004 | 43 | 0.050 |
Why?
| | Area Under Curve | 1 | 2005 | 330 | 0.050 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
| | Dopamine Antagonists | 1 | 2003 | 25 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 249 | 0.050 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 226 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 312 | 0.050 |
Why?
| | Visual Fields | 1 | 2004 | 115 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 552 | 0.050 |
Why?
| | Mental Recall | 2 | 1996 | 222 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 232 | 0.050 |
Why?
| | Action Potentials | 6 | 1993 | 506 | 0.050 |
Why?
| | Haloperidol | 1 | 2002 | 33 | 0.050 |
Why?
| | Age of Onset | 2 | 2007 | 551 | 0.050 |
Why?
| | Head | 1 | 2004 | 120 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 592 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2005 | 724 | 0.050 |
Why?
| | Purkinje Cells | 5 | 1988 | 64 | 0.050 |
Why?
| | Chromosome Disorders | 2 | 1999 | 45 | 0.050 |
Why?
| | Radioligand Assay | 1 | 2001 | 37 | 0.040 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2001 | 15 | 0.040 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2001 | 17 | 0.040 |
Why?
| | Lod Score | 1 | 2001 | 62 | 0.040 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2001 | 19 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2001 | 36 | 0.040 |
Why?
| | Exons | 3 | 2015 | 358 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2001 | 64 | 0.040 |
Why?
| | Cloning, Molecular | 2 | 2000 | 540 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2001 | 55 | 0.040 |
Why?
| | Visual Cortex | 1 | 2002 | 84 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2001 | 193 | 0.040 |
Why?
| | Movement | 1 | 2004 | 293 | 0.040 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 162 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2007 | 790 | 0.040 |
Why?
| | Hallucinations | 1 | 2001 | 31 | 0.040 |
Why?
| | Cell Count | 1 | 2001 | 320 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 2021 | 76 | 0.040 |
Why?
| | Fornix, Brain | 1 | 2000 | 5 | 0.040 |
Why?
| | Family Health | 1 | 2001 | 191 | 0.040 |
Why?
| | Denervation | 1 | 2000 | 27 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 382 | 0.040 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2000 | 49 | 0.040 |
Why?
| | Point Mutation | 2 | 1999 | 243 | 0.040 |
Why?
| | Multifactorial Inheritance | 1 | 2001 | 202 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 902 | 0.040 |
Why?
| | Blotting, Western | 3 | 2005 | 1187 | 0.040 |
Why?
| | Blotting, Northern | 2 | 2005 | 204 | 0.040 |
Why?
| | Binding Sites | 1 | 2002 | 1329 | 0.040 |
Why?
| | Cocaine | 1 | 2001 | 160 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1837 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 983 | 0.040 |
Why?
| | Fathers | 1 | 1999 | 51 | 0.040 |
Why?
| | Genetic Testing | 1 | 2001 | 478 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1989 | 594 | 0.030 |
Why?
| | Self Medication | 1 | 1998 | 12 | 0.030 |
Why?
| | Cell Movement | 1 | 2002 | 965 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2021 | 281 | 0.030 |
Why?
| | Cholinergic Agents | 1 | 1998 | 18 | 0.030 |
Why?
| | Genetics, Population | 1 | 1999 | 214 | 0.030 |
Why?
| | Electric Conductivity | 2 | 1998 | 84 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1998 | 140 | 0.030 |
Why?
| | Heterozygote | 1 | 1998 | 315 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2001 | 1716 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1997 | 5 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2000 | 573 | 0.030 |
Why?
| | Conditioning, Classical | 2 | 2008 | 120 | 0.030 |
Why?
| | Parents | 2 | 2015 | 1403 | 0.030 |
Why?
| | Base Sequence | 3 | 2009 | 2190 | 0.030 |
Why?
| | Memory Disorders | 1 | 1998 | 193 | 0.030 |
Why?
| | Age Factors | 2 | 2006 | 3333 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2013 | 319 | 0.030 |
Why?
| | Sensory Thresholds | 1 | 1996 | 31 | 0.030 |
Why?
| | Motor Activity | 2 | 1992 | 721 | 0.030 |
Why?
| | Nerve Fibers | 1 | 1995 | 104 | 0.030 |
Why?
| | Receptors, Glutamate | 1 | 1995 | 26 | 0.030 |
Why?
| | Nerve Growth Factors | 1 | 1995 | 78 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 195 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 331 | 0.030 |
Why?
| | Placenta | 1 | 2021 | 780 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 6048 | 0.030 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1994 | 14 | 0.030 |
Why?
| | Cholinergic Fibers | 1 | 1993 | 19 | 0.030 |
Why?
| | Aging | 2 | 1999 | 1966 | 0.030 |
Why?
| | Horseradish Peroxidase | 1 | 1993 | 26 | 0.030 |
Why?
| | Orientation | 1 | 1994 | 50 | 0.020 |
Why?
| | Neuromuscular Junction | 1 | 1994 | 65 | 0.020 |
Why?
| | Genetic Engineering | 1 | 1994 | 93 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 1995 | 1054 | 0.020 |
Why?
| | Synaptic Vesicles | 1 | 1993 | 40 | 0.020 |
Why?
| | Axonal Transport | 1 | 1993 | 26 | 0.020 |
Why?
| | Chronic Disease | 1 | 1999 | 1813 | 0.020 |
Why?
| | Temporal Lobe | 1 | 1993 | 104 | 0.020 |
Why?
| | Tissue Banks | 1 | 2013 | 17 | 0.020 |
Why?
| | Habituation, Psychophysiologic | 1 | 1993 | 58 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2013 | 44 | 0.020 |
Why?
| | DNA Probes | 1 | 2013 | 59 | 0.020 |
Why?
| | Nomifensine | 1 | 1992 | 2 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 2013 | 52 | 0.020 |
Why?
| | Poly A | 1 | 1993 | 50 | 0.020 |
Why?
| | Genes, MHC Class I | 1 | 2013 | 36 | 0.020 |
Why?
| | Receptors, sigma | 1 | 1992 | 2 | 0.020 |
Why?
| | Sympathomimetics | 1 | 1992 | 19 | 0.020 |
Why?
| | Peptides | 1 | 1999 | 995 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 1782 | 0.020 |
Why?
| | Biogenic Monoamines | 1 | 1992 | 15 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1992 | 71 | 0.020 |
Why?
| | Benzylamines | 1 | 1992 | 43 | 0.020 |
Why?
| | Tubocurarine | 1 | 1992 | 6 | 0.020 |
Why?
| | Muscles | 1 | 1994 | 333 | 0.020 |
Why?
| | Mecamylamine | 1 | 1992 | 6 | 0.020 |
Why?
| | Levodopa | 1 | 1992 | 41 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 1992 | 43 | 0.020 |
Why?
| | Parasympatholytics | 1 | 1992 | 11 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 1992 | 56 | 0.020 |
Why?
| | Microelectrodes | 1 | 1992 | 47 | 0.020 |
Why?
| | Nervous System | 1 | 1992 | 70 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2012 | 20 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 341 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 69 | 0.020 |
Why?
| | Temperature | 1 | 1995 | 679 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2002 | 8265 | 0.020 |
Why?
| | DNA Replication | 1 | 1993 | 251 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1496 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1370 | 0.020 |
Why?
| | RNA | 2 | 2013 | 940 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2930 | 0.020 |
Why?
| | Introns | 2 | 2003 | 254 | 0.020 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1994 | 419 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 458 | 0.020 |
Why?
| | Risk Assessment | 1 | 1999 | 3671 | 0.020 |
Why?
| | Adenylate Cyclase Toxin | 1 | 1989 | 6 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1989 | 15 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1989 | 24 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 1989 | 19 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2009 | 85 | 0.020 |
Why?
| | Autoanalysis | 1 | 1989 | 8 | 0.020 |
Why?
| | Adenylyl Cyclases | 1 | 1989 | 60 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 1994 | 579 | 0.020 |
Why?
| | Electrochemistry | 1 | 1989 | 73 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1075 | 0.020 |
Why?
| | Yohimbine | 1 | 1988 | 11 | 0.020 |
Why?
| | Dioxins | 1 | 1988 | 7 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2882 | 0.020 |
Why?
| | Dioxanes | 1 | 1988 | 10 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 1989 | 153 | 0.020 |
Why?
| | Receptors, Adrenergic | 1 | 1988 | 20 | 0.020 |
Why?
| | Gene Dosage | 1 | 2009 | 148 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2009 | 322 | 0.020 |
Why?
| | Tyramine | 1 | 1988 | 8 | 0.020 |
Why?
| | Pulse | 1 | 1988 | 27 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2010 | 218 | 0.020 |
Why?
| | Fluphenazine | 1 | 1987 | 4 | 0.020 |
Why?
| | Saliva | 1 | 1989 | 249 | 0.020 |
Why?
| | Audiometry, Evoked Response | 1 | 1987 | 15 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 427 | 0.020 |
Why?
| | Stereoisomerism | 1 | 1987 | 104 | 0.020 |
Why?
| | Autoradiography | 2 | 1997 | 64 | 0.020 |
Why?
| | Tyrosine | 1 | 1988 | 222 | 0.020 |
Why?
| | Mutation | 2 | 2015 | 4089 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 198 | 0.020 |
Why?
| | alpha Catenin | 1 | 2005 | 11 | 0.010 |
Why?
| | Transcription Factors | 1 | 1994 | 1741 | 0.010 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 47 | 0.010 |
Why?
| | ROC Curve | 1 | 2007 | 614 | 0.010 |
Why?
| | Microarray Analysis | 1 | 2005 | 117 | 0.010 |
Why?
| | Patient Selection | 1 | 2009 | 719 | 0.010 |
Why?
| | Suicide | 1 | 1993 | 720 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 561 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1987 | 284 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1489 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2002 | 41 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2009 | 1406 | 0.010 |
Why?
| | Artifacts | 1 | 2002 | 139 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 2112 | 0.010 |
Why?
| | Diet | 1 | 1988 | 1273 | 0.010 |
Why?
| | Contig Mapping | 1 | 1998 | 10 | 0.010 |
Why?
| | Genes, Duplicate | 1 | 1998 | 4 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1998 | 80 | 0.010 |
Why?
| | Receptors, Presynaptic | 1 | 1998 | 9 | 0.010 |
Why?
| | Macaca radiata | 1 | 1997 | 15 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 1821 | 0.010 |
Why?
| | Autopsy | 1 | 1997 | 94 | 0.010 |
Why?
| | Organ Specificity | 1 | 1997 | 312 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 397 | 0.010 |
Why?
| | Species Specificity | 1 | 1996 | 574 | 0.010 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 1995 | 42 | 0.010 |
Why?
| | Gene Amplification | 1 | 1995 | 120 | 0.010 |
Why?
| | Isomerases | 1 | 1994 | 8 | 0.010 |
Why?
| | Protein Disulfide-Isomerases | 1 | 1994 | 11 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1994 | 55 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 512 | 0.010 |
Why?
| | Endopeptidases | 1 | 1994 | 82 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 304 | 0.010 |
Why?
| | Molecular Biology | 1 | 1994 | 59 | 0.010 |
Why?
| | tau Proteins | 1 | 1995 | 115 | 0.010 |
Why?
| | Glycosylation | 1 | 1994 | 172 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1994 | 145 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1994 | 337 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1463 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2155 | 0.000 |
Why?
| | Idazoxan | 1 | 1988 | 1 | 0.000 |
Why?
| | Phentolamine | 1 | 1988 | 20 | 0.000 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1988 | 19 | 0.000 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1988 | 61 | 0.000 |
Why?
| | Rats, Inbred F344 | 1 | 1988 | 268 | 0.000 |
Why?
| | Desipramine | 1 | 1988 | 10 | 0.000 |
Why?
| | Magnesium | 1 | 1987 | 155 | 0.000 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1499 | 0.000 |
Why?
|
|
Freedman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|